126 related articles for article (PubMed ID: 9498772)
1. Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.
Shafren DR; Dorahy DJ; Thorne RF; Kinoshita T; Barry RD; Burns GF
J Immunol; 1998 Mar; 160(5):2318-23. PubMed ID: 9498772
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
3. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
[TBL] [Abstract][Full Text] [Related]
4. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
[TBL] [Abstract][Full Text] [Related]
5. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
6. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
Newcombe NG; Beagley LG; Christiansen D; Loveland BE; Johansson ES; Beagley KW; Barry RD; Shafren DR
J Virol; 2004 Nov; 78(22):12677-82. PubMed ID: 15507656
[TBL] [Abstract][Full Text] [Related]
7. Two clusters of mutations map distinct receptor-binding sites of echovirus 11 for the decay-accelerating factor (CD55) and for canyon-binding receptors.
Rezaikin AV; Novoselov AV; Sergeev AG; Fadeyev FA; Lebedev SV
Virus Res; 2009 Oct; 145(1):74-9. PubMed ID: 19540285
[TBL] [Abstract][Full Text] [Related]
8. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.
Shafren DR; Dorahy DJ; Ingham RA; Burns GF; Barry RD
J Virol; 1997 Jun; 71(6):4736-43. PubMed ID: 9151867
[TBL] [Abstract][Full Text] [Related]
9. Effect of tandem forms of DAF(CD55) on complement-mediated xenogeneic cell lysis.
Miyagawa S; Fukuta D; Kitano E; Kobayashi C; Fumimoto Y; Shirasu A; Hattori H; Shirakura R; Fukuzawa M
Xenotransplantation; 2006 Sep; 13(5):433-9. PubMed ID: 16925667
[TBL] [Abstract][Full Text] [Related]
10. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
[TBL] [Abstract][Full Text] [Related]
11. Characterization of echoviruses that bind decay accelerating factor (CD55): evidence that some haemagglutinating strains use more than one cellular receptor.
Powell RM; Schmitt V; Ward T; Goodfellow I; Evans DJ; Almond JW
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1707-13. PubMed ID: 9680134
[TBL] [Abstract][Full Text] [Related]
12. Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF.
Spiller OB; Goodfellow IG; Evans DJ; Almond JW; Morgan BP
J Infect Dis; 2000 Jan; 181(1):340-3. PubMed ID: 10608785
[TBL] [Abstract][Full Text] [Related]
13. Cytolytic replication of coxsackievirus B2 in CAR-deficient rhabdomyosarcoma cells.
Polacek C; Ekström JO; Lundgren A; Lindberg AM
Virus Res; 2005 Nov; 113(2):107-15. PubMed ID: 15964091
[TBL] [Abstract][Full Text] [Related]
14. Role of class I human leukocyte antigen molecules in early steps of echovirus infection of rhabdomyosarcoma cells.
Chevaliez S; Balanant J; Maillard P; Lone YC; Lemonnier FA; Delpeyroux F
Virology; 2008 Nov; 381(2):203-14. PubMed ID: 18823925
[TBL] [Abstract][Full Text] [Related]
15. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
[TBL] [Abstract][Full Text] [Related]
17. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.
Milstone AM; Petrella J; Sanchez MD; Mahmud M; Whitbeck JC; Bergelson JM
J Virol; 2005 Jan; 79(1):655-60. PubMed ID: 15596863
[TBL] [Abstract][Full Text] [Related]
18. Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of human colon cancer cells.
Agrez MV; Shafren DR; Gu X; Cox K; Sheppard D; Barry RD
Virology; 1997 Dec; 239(1):71-7. PubMed ID: 9426447
[TBL] [Abstract][Full Text] [Related]
19. Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF.
Okura E; Ishimaru A; Yamamoto A; Nakatsu S; Shirakura R; Okabe M; Sawa Y; Fukuzawa M; Okumura M; Miyagawa S
Xenotransplantation; 2008; 15(6):365-73. PubMed ID: 19152664
[TBL] [Abstract][Full Text] [Related]
20. Echovirus infection of rhabdomyosarcoma cells is inhibited by antiserum to the complement control protein CD59.
Goodfellow IG; Powell RM; Ward T; Spiller OB; Almond JW; Evans DJ
J Gen Virol; 2000 May; 81(Pt 5):1393-401. PubMed ID: 10769083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]